By Adria Calatayud
Sanofi said it would stop a late-stage study of an experimental treatment for a rare immune disorder after concluding the drug was unlikely to deliver sufficient efficacy.
The French drugmaker said Wednesday that it would consider whether to continue other studies for the drug, riliprubart, currently under way.
The study termination deals an early setback to Sanofi's newly appointed chief executive, Belen Garijo, who took the helm last month after leading Germany's Merck KGaA since 2021.
The decision to stop the trial for riliprubart in patients with a rare neurological condition known as chronic inflammatory demyelinating polyneuropathy followed an interim analysis by an independent data-monitoring committee that showed the study was unlikely to achieve sufficient efficacy, the company said.
The study evaluated whether patients who didn't respond to the standard-of-care therapy could be treated with riliprubart, which is designed to block an enzyme that drives key inflammatory mechanisms behind the disease.
The continuation of other studies with riliprubart, including another phase 3 trial for chronic inflammatory demyelinating polyneuropathy, will be evaluated in light of the data, Sanofi said.
The company said it doesn't expect to book any significant cost from the termination of the study, and that its guidance for 2026 remains unchanged.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
June 10, 2026 02:18 ET (06:18 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.